DNL201 Chemical Structure oral LRRK2 kinase inhibitor - Denali Therapeutics Inc., South San Francisco, CA

oral LRRK2 kinase inhibitor

Ph. I completed in Parkinson’s Disease

HTS, SBDD, and CNS-focused opt.

Sci. Transl. Med.

Denali Therapeutics Inc., South San Francisco, CA

Context. DNL201 (Denali Therapeutics) is an oral, CNS-penetrating, ATP-competitive leucine-rich repeat kinase 2 (LRRK2) inhibitor being developed for Parkinson’s disease (PD). PD remains incurable; current treatment options only alleviate…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.